Blue Horseshoe Stocks: ATVI Options & More

Activision Blizzard. Inc. ATVI

We focused on stocks quite a bit earlier on in the week, so this morning we wanted to take the opportunity to put another potential options play into the mix. We’re constantly looking for company’s that have just reported earnings, which gives us the potential for the volatility that we want.

In the case of ATVI, while its quarterly figures were lacking, the tock was at a bottom, and appears to want to go green today. We will put the ATVI Weekly $42-43.50 Calls on watch this morning, and monitor for the remainder of the week for a possible rebound off of what was its new 52-week low, registered on Monday.



SPDR S&P500 ETF (SPY)

Our regular readers are well aware of our fondness for the SPY ETF. We have taken advantage of it on many occasions. A quick peek into our archives reveals that today is the 114th time we’ve mentioned the SPY in our newsletters. It’s a well that we continue to draw from, with no indications of that ever changing.

Today, after such a big move yesterday wherein the SPY broke its 200DMA, we want to look for  continuation of the bullish behavior we’re observing. We will designate the SPY Weekly $274.50-275.50 Calls as ones to watch as we head through this midweek.


Extended Watchlist:
DBD, AVLR, FCX, ADOM, RWLK, YGYI, SN

Blue Horseshoe Stocks: PBR Options Recap & More

Petroleo Brasileiro SA (Petrobras) PBR – Recap

Yesterday morning, one of the primary focal points our premarket report was a pair of PBR options contracts, the PBR Weekly $14 & 14.50 Calls.

We cited the stock’s volatility and rapid rise over recent relative lows as the reasons for our interest, and despite yet another reversal for the markets in general, we got very solid single-session results for our PBR ideas. The $14′s traded up 95% from .21-.41, while the $14.50′s logged a double-bagger as they ran from  .05-.11, a gain of 120%

PBR is gapping up once again this morning, so we expect these figures to open up even higher. We will then be looking for a possible dip-and-rip scenario.


BioXcel Therapeutics, Inc. BTAI

We mentioned BTAI for the first time in yesterday morning’s extended watchlist, and got a solid first day performance from that stock as well, as it went in the books as the 2nd highest gainer on the Nasdaq for the session.

From a low of 4.00, BTAI went on to hit a high of 5.84, which worked out to a respectable 46% rise that also bucked the overall trend of the day. The move was facilitated by news that the company achieved positive human proof-of-concept data for acute treatment of agitation in patients with Alzheimer’s Disease, and other degenerative neural disorders. (>>View PR)


Extended Watchlist:
W, APU, ARGX, MYSZ, SN, XPO, EPZM, AMID, PROP, SING

Blue Horseshoe Stocks: FRO, OPK, WLGC & More

Frontline, Ltd. FRO

At the beginning of this month when we first began looking at FRO, the stock was trading at a low of 1.33. It took barely a week for the stock to start inching its way up, and it has continued to do so up to the present.

By the time we re-flagged it in Friday’s morning report, it had already cracked the $2.00-mark, and we did mention that the level of momentum was primed to allow for further opportunities.

This morning FRO continues to push the envelope, setting a new high in premarket trading action. This morning’s top figure of 2.64 puts us just slightly short of double-bagger status, having shown us an increase of 98% from the lows we observed the week before last.

It can be argued that the bolstering of activity seen on FRO (and other shipping plays) is due to the continuing fall of oil prices which translates to savings at the pump.


Opko Health, Inc. OPK

OPK is catching our attention in the premarket as well, as a result of an agreement announced this morning with pharma-giant Pfizer to develop and commercialize one of Opko’s highly promising products which combats Growth Hormone deficiency. Peruse the following PR to find out more; the development certainly lands OPK a spot on our watchlist to kick off the week.

In instances like these where a play is sent through the roof on substantial news, we look for the resulting profit-taking to pull the stock back, where we wait to take advantage of a possible dip-and-rip scenario.

OPKO Health, Inc. (OPK) and Pfizer Inc. (PFE) announced today that they have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD)… hGH-CTP has the potential to reduce the required dosing frequency of human growth hormone to a single weekly injection from the current standard of one injection per day. >> FULL PR


WordLogic Corp. WLGC

Speaking of significant news, WLGC forces its way into our vernacular this morning on the heels of the announcement that the company will be teaming up with energy-leviathan General Electric (GE) in order to “monetize specific patented intellectual property in General Electric’s portfolio.”

With such a high-profile bedfellow, WLGC will instantly gain new recognition, and it will be very interesting to see how that translates to the chart.


Notable Gainers from Friday’s Extended Watchlist

Oncothyreon, Inc. ONTYRange: 1.69-2.05   Gain: 21%

Organovo Holdings, Inc. ONVORange: 5.82-6.50  Gain: 11%


Extended Watchlist:
TLM, SN, BLRX, KEG, HGSH, CPST